Stocktoria
QIAGEN N.V. QGEN
NYSE · XNYS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1996-09-01
QIAGEN N.V. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 62.2% | 48.9% | 62.8% | 64.7% | 64.4% |
| Operating margin | 22.3% | 4.9% | 20.9% | 24.8% | 28.0% |
| Net margin | 20.3% | 4.2% | 17.4% | 19.8% | 22.8% |
| FCF margin | 21.7% | 25.6% | 15.8% | 27.4% | 19.9% |
| Return on assets | 6.8% | 1.5% | 5.6% | 6.7% | 8.3% |
| Return on equity | 11.2% | 2.3% | 9.0% | 12.2% | 16.6% |
| Debt / equity | 0.44× | 0.39× | 0.40× | 0.54× | 0.63× |
| Current ratio | 3.90 | 1.88 | 1.99 | 2.46 | 1.39 |
| Revenue growth | 5.7% | 0.7% | -8.2% | -4.9% | 20.4% |
Source: SEC EDGAR filings · CIK 0001015820 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.